Macrogenics (MGNX) Current Deferred Revenue (2012 - 2026)

Macrogenics (MGNX) has 15 years of Current Deferred Revenue data on file, last reported at $68.0 million in Q1 2026.

• On a quarterly basis, Current Deferred Revenue rose 335.29% year-over-year to $68.0 million in Q1 2026; TTM through Mar 2026 was $68.0 million, a 335.29% increase from a year earlier, with the FY2025 full-year figure at $10.9 million, down 33.08% from the prior year.
• Current Deferred Revenue for Q1 2026 stood at $68.0 million, up from $10.9 million in the prior quarter.
• Over the last five years, Current Deferred Revenue for MGNX reached as high as $100.0 million in Q1 2023 and fell as low as $7.1 million in Q3 2022.
• Historically, Current Deferred Revenue has averaged $23.7 million across 5 years, with a median of $16.3 million in 2024.
• Across the five-year window, Current Deferred Revenue soared 626.19% in 2022 and plunged 77.16% in 2024, its largest moves.
• Year by year, Current Deferred Revenue stood at $10.0 million in 2022, then jumped by 116.77% to $21.7 million in 2023, then dropped by 24.63% to $16.3 million in 2024, then slumped by 33.08% to $10.9 million in 2025, then surged by 522.59% to $68.0 million in 2026.
• Per Business Quant data, the three most recent Current Deferred Revenue figures were $68.0 million in Q1 2026, $10.9 million in Q4 2025, and $10.3 million in Q3 2025.